Aspirin Market Growth and Key Developments

The aspirin market is set to reach $3.51B by 2030. Sun Pharma's acquisition of Taro and Bayer's digital health partnership reshape the competitive landscape for buyers and distributors.

Who is this relevant for?

Pharmaceutical buyers sourcing shortage medicines
Distributors monitoring sourcing opportunities

The global aspirin market is projected to hit $3.51 billion by 2030, expanding at a 5.8% CAGR. Steady growth comes from preventive healthcare trends, rising cardiovascular disease awareness, and advances in drug delivery and personalized dosing.

Leading players include Bayer, Teva, Novartis, Pfizer, Sanofi, and Sun Pharma. In May 2024, Sun Pharma closed its acquisition of Taro Pharmaceutical Industries, a manufacturer of acetylsalicylic acid capsules. The deal strengthens Sun Pharma's hold on off-patent and OTC products, directly reshaping sourcing dynamics.

Strategic partnerships are also driving change. Bayer teamed up with Huma Therapeutics to launch an online heart risk assessment tool, aiming to broaden consumer engagement and drive aspirin demand.

The market breaks down by product type (prescription vs OTC), route of administration, dosage forms, and applications. For buyers and distributors, these developments mean a consolidating market with a stronger push toward cardiovascular prevention and wider OTC access. Keeping tabs on major players' strategies will be essential for informed sourcing decisions.